Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
Sign Up to like & getrecommendations! Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0688-4
Abstract: SummaryPurpose To determine the maximum tolerated dose (MTD) of F14512, a topoisomerase II inhibitor designed to target cancer cells through the polyamine transport system, (three-hour daily infusion given for 3 consecutive days every 3 weeks) in… read more here.
Keywords: topoisomerase inhibitor; resistant ovarian; study; platinum refractory ... See more keywords
Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Current Oncology Reports"
DOI: 10.1007/s11912-018-0693-y
Abstract: Purpose of ReviewAdvanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key… read more here.
Keywords: carcinoma; level evidence; platinum refractory; urothelial carcinoma ... See more keywords
HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2020.11.035
Abstract: OBJECTIVE To describe our single-institution oncologic outcomes of patients who received neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS We compared clinicopathologic information and outcomes for all… read more here.
Keywords: chemotherapy; platinum; disease; platinum refractory ... See more keywords
Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz252.037
Abstract: Abstract Background To evaluate the efficacy and safety of apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma. Methods In this phase 2, single-arm, prospective study, we recruited patients aged 18–65… read more here.
Keywords: recurrent metastatic; platinum; resistant platinum; platinum refractory ... See more keywords
Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e17502
Abstract: e17502 Background: To evaluate the efficacy and safety of apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma. Methods: In this phase 2, single-arm, prospective study, we recruited patients aged 18–65… read more here.
Keywords: platinum refractory; platinum resistant; refractory recurrent; platinum ... See more keywords
Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Management and Research"
DOI: 10.2147/cmar.s201048
Abstract: Purpose Patients with gastrointestinal neuroendocrine carcinoma (GI-NEC) have poor prognoses. Although platinum-based combination chemotherapy is commonly used as first-line treatment, the benefit of amrubicin (AMR) and salvage chemotherapy in those who develop platinum-refractory GI-NEC remains… read more here.
Keywords: chemotherapy; platinum refractory; neuroendocrine carcinoma; refractory nec ... See more keywords
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s286529
Abstract: Objective Anlotinib, an oral small-molecular tyrosine kinase inhibitor (TKI) on tumor angiogenesis and growth, has a wide spectrum of inhibitory effects on targets such as vascular endothelial growth factor receptors 2/3 (VEGFR2/3), etc. The efficacy… read more here.
Keywords: platinum refractory; ovarian cancer; cancer; platinum resistant ... See more keywords
Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report
Sign Up to like & getrecommendations! Published in 2018 at "OncoTargets and therapy"
DOI: 10.2147/ott.s162985
Abstract: Background Ovarian adenosquamous carcinoma is an extremely rare type of ovarian histology. Platinum-refractory disease is also uncommon, but can be fatal because of the lack of available treatment options. To date, there is no study… read more here.
Keywords: platinum refractory; adenosquamous carcinoma; ovarian adenosquamous;
New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms222413324
Abstract: The pro-apoptotic tumor suppressor BIN1 inhibits the activities of the neoplastic transcription factor MYC, poly (ADP-ribose) polymerase-1 (PARP1), and ATM Ser/Thr kinase (ATM) by separate mechanisms. Although BIN1 deficits increase cancer-cell resistance to DNA-damaging chemotherapeutics,… read more here.
Keywords: cancer; cancer cells; platinum refractory; cisplatin sensitivity ... See more keywords
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
Sign Up to like & getrecommendations! Published in 2020 at "Vaccines"
DOI: 10.3390/vaccines8020191
Abstract: Background: Previous locoregional treatment could affect the response to nivolumab in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The aim of this study is to evaluate the impact of the clinicopathological characteristics… read more here.
Keywords: response; treatment; platinum refractory; locoregional treatment ... See more keywords